Patients with chronic kidney disease (CKD) are more likely to sustain adverse cardiac events following percutaneous coronary intervention (PCI). Inflammation is an important component of CKD and is associated with poor prognosis. Those with high residual inflammatory risk have increased risks of coronary events following PCI. Therefore, we investigated the impact baseline highsensitivity C-reactive protein (hsCRP) has on outcomes among CKD patients undergoing PCI.